Clinical Trials Logo

Drug Hypersensitivity clinical trials

View clinical trials related to Drug Hypersensitivity.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT06263140 Completed - Clinical trials for Vitamin D Deficiency

Vitamin D Levels in Non-immediate Drug Hypersensitivity Case-control Study

Start date: May 30, 2021
Phase:
Study type: Observational

Serum vitamin D levels in drug-induced non-immediate reactions

NCT ID: NCT05706246 Completed - Drug Allergy Clinical Trials

Perioperative Hypersensitivity in Children

Start date: June 30, 2020
Phase: N/A
Study type: Interventional

There are limited studies on perioperative hypersensitivity (POH) reactions in children. The diagnosis of POH might be underestimated due to the difficulty of recognizing the reactions. Anaphylaxis may go unnoticed due to the unconscious state of the patient. Urticaria may be overlooked due to the sterile covers. This study aimed to evaluate POH reactions prospectively.

NCT ID: NCT05269082 Completed - Clinical trials for Drug Hypersensitivity

A Study to Assess the Hypersensitivity to TAK-880 Compared to Gammagard S/D in Blood of Children, Teenagers and Adults

Start date: April 5, 2022
Phase:
Study type: Observational

The aim of this study is to find out whether TAK-880 creates hypersensitivity reactions compared to Gammagard S/D by testing blood taken from participants who have a higher risk of becoming hypersensitive to immunoglobulin products. This study is about collecting data available in the participant's medical record. No study medicines will be provided to participants in this study. Each participant will fill out a study questionnaire during a routine doctor visit. Blood will be taken from participants who have a higher risk of developing hypersensitivity reactions to immunoglobulin products.

NCT ID: NCT05090527 Completed - Penicillin Allergy Clinical Trials

Penicillin Allergy Delabeling Project

PenProv
Start date: July 28, 2021
Phase: N/A
Study type: Interventional

A investigational study to establish: 1. A validated cllinical pathway for delabeling declared Penicillin allergiy outside allergologic departments. 2. A survey to examine anesthesiologists attitudes and knowledge about penicillin delabeling. 3. A qualitative focus group study investigating barriers and facilitators in penicillin delabeling among hospital nurses and physichians. 2. Implement the pathway for delabeling declared penicillin allergy outside allergologic clinics across the Western Norway health region.

NCT ID: NCT05020327 Completed - Penicillin Allergy Clinical Trials

Inpatient Penicillin Allergy Delabeling Study

Start date: September 22, 2021
Phase: Phase 4
Study type: Interventional

The study will identify pediatric patients 3-18 years old who have penicillin allergy label in the electronic medical record. Those who are identified will be stratified into no-risk, low-risk and high-risk category using a screening questionnaire. The following definitions will be followed: No-risk: Patients who are historically labeled with penicillin allergy in the EMR based on family history alone OR those who have tolerated penicillin after a concerning incident without any reaction OR with penicillin allergy label but deny any history of reaction to any form of penicillin on screening questionnaire Low-risk: Patients with previous reaction not suggestive of anaphylaxis (defined below) AND not requiring hospitalization for the reaction OR reaction considered non- immunologic (e.g. diarrhea, nausea, yeast vaginitis) OR exposure to penicillin- containing antibiotic after the date of reported reaction with no anaphylaxis and hospitalization AND no serious types of delayed reactions such as Steven- Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), acute interstitial nephritis (AIN), drug-induced hepatitis or other documented organ injury, drug rash eosinophilia systemic symptoms (DRESS), hemolytic anemia, drug-induced cytopenia, and serum sickness. Patients who had delayed reaction (onset more than 24 hours) of isolated, non-progressive symptoms (such as rash/hives alone) also belong to this group. High-risk: Patients with penicillin allergy label on EMR with previous reaction suggestive of anaphylaxis (defined below) OR requiring hospitalization/epinephrine administration for the reaction OR reactions considered immunologic (angioedema, joint pains) OR involving serious types of reactions such as Steven-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), acute interstitial nephritis (AIN), drug-induced hepatitis or other documented organ injury, drug rash eosinophilia systemic symptoms (DRESS), hemolytic anemia, drug-induced cytopenia, and serum sickness. Patients who were previously diagnosed with penicillin allergy by an allergist also belong to the high-risk group. Patients in the no-risk group will be immediately delabeled. Patients in the high-risk group will be referred to allergy/immunology for further work up. The focus of this study is to identify the patients who belong to the low-risk group. This group of patients will be subjected to graded oral amoxicillin challenge testing. Those who will have reactions compatible with allergy will have their allergy status retained in the electronic medical record. Those that will not have reactions or those that will have reactions that are not compatible with allergy will be delabeled in the electronic medical record.

NCT ID: NCT04827602 Completed - Clinical trials for Drug Hypersensitivity

Drug Allergy Labels After Drug Allergy Investigation

Start date: April 15, 2021
Phase:
Study type: Observational

The aim of this study is to investigate the degree of match between the drug allergy label in the hospital's electronic health record and primary care's electronic health record among patients who previously have been drug allergy tested.

NCT ID: NCT04620746 Completed - Penicillin Allergy Clinical Trials

Penicillin Allergy Testing in STD Clinics

Start date: June 1, 2021
Phase: Phase 4
Study type: Interventional

Demonstration project to implement penicillin allergy testing in STD outpatients using a questionnaire and pen allergy testing

NCT ID: NCT04421638 Completed - Clinical trials for Drug Hypersensitivity

Cephalosporin Hypersensitivity

CephALL
Start date: January 30, 2020
Phase:
Study type: Observational

Background : Although the hypersensitivity reactions to cephalosporins have been recently a more focused subject, studies on the cephalosporin as an allergen are significantly less frequent that those regarding penicillins. Most of the available data regards cephalosporin sensitization in patients previously allergic to penicillin. Like penicillins, cephalosporins represent one of the most prescribed classes of antibiotics. The diagnosis of cephalosporin hypersensitivity is based mainly on clinical history, skin tests (ST) and drug provocation tests (DPT). This succession of tests, performed in specialized services, allows to eliminate responsibility for the drug in many cases (80-85%). The drug allergy work-up also allows to identify profiles of allergy to cephalosporins, with different patterns of cross-reactivity. Objective: To analyse the characteristics of patients studied in our Unit for suspicion of cephalosporin hypersensitivity. Methods: This retrospective study will comprise all the patients who attended the allergy service of the UH of Montpellier from 1997 till 2018 with a clinical history evocative of cephalosporin drug hypersensitivity reaction (DHR), who underwent a drug allergy work up and who gave their consent to be included in the study . The Patients are selected from the Drug Allergy & Hypersensitivity Database (DAHD).

NCT ID: NCT04252326 Completed - Clinical trials for Adverse Drug Reactions

The Knowledge, Attitudes and Practices of Healthcare Workers on Drug Hypersensitivity Reactions in Children

KAPHWDHRC
Start date: January 1, 2020
Phase: N/A
Study type: Interventional

Adverse drug reactions are an important public health consern that affects physician prescriptions and practice. The responsibilities of healthcare professionals in monitoring, prevention, treatment and reporting of drug hypersensitivity reactions and drug allergies are essential for patient safety. Providing drug safety must be one of the main goals to be achieved for every member of our society. In our study, we planned to evaluate the knowledge, attitudes, and behaviors of healthcare workers in our country about drug hypersensitivity reactions in pediatric patients and to determine the risk factors that may affect them.

NCT ID: NCT03942731 Completed - Penicillin Allergy Clinical Trials

Penicillin Allergy Testing and Resensitization Rate

Penicillin
Start date: February 1, 2019
Phase:
Study type: Observational

Penicillin is one of the earliest discovered antibiotics and a drug of choice for several infections. Up to 10 to 20% of all patients in clinical trial are labeled as penicillin allergic. Most of these patients do not have a true allergy but few have had it verified. Approximately 80% of patients with IgE-mediated penicillin allergy lose their sensitivity after 10 years. Several studies have been conducted denying the risk of sensitization following negative testing of penicillin allergy. Investigators have not had the same experience and have therefore decided to conduct a retrospective study review of 83 adult outpatients with a distant penicillin allergy label and evaluate outcomes of skin retesting six weeks following Drug Provocation Test and challenge.